Preferred Label : capmatinib;

MeSH synonym : 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide; 2-fluoro-N-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide;

MeSH hyponym : 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- b)(1,2,4)triazin-2-yl)benzamide dihydrochloride monohydrate; Tabrecta; capmatinib hydrochloride; capmatinib metabolite M18; CNJ294; 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide; capmatinib hydrochloride anhydrous; 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide dihydrochloride; INCB-28060 free base; INCB-28060; NVP-INC280-NX; INC-280; INCB28060; NVP-INC280; CMC583; 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic acid; capmatinib metabolite M13;

MeSH Related Number : C2A374O70X; DD8K9FL3YS; PZ22FPE9O7; Z0V2EW20JR;

UNII : TY34L4F9OZ;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3406127/fr/tabrecta-capmatinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2023
false
false
false
France
evaluation of the transparency committee
cancer
Cell
cells
capmatinib
carcinoma, non-small-cell lung
neoplasm, malignant
Cancer
due to
bronchus, nos
"u" lymphocyte
capmatinib

---
https://www.has-sante.fr/jcms/p_3359657/fr/tabrecta-capmatinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2022
false
false
false
France
capmatinib
bronchial neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
capmatinib
antineoplastic agents
Product containing precisely capmatinib 150 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely capmatinib 200 milligram/1 each conventional release oral tablet (clinical drug)
evaluation of the transparency committee
capmatinib
carcinoma, non-small-cell lung

---
https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta
2022
false
false
false
Netherlands
French
English
treatment outcome
capmatinib
capmatinib
syndication feed
summary of product characteristics
package leaflet
drug evaluation
protein kinase inhibitors
protein kinase inhibitors
adult
carcinoma, non-small-cell lung
administration, oral
carcinoma, non-small-cell lung
mutation
product surveillance, postmarketing
Product containing precisely capmatinib 150 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely capmatinib 200 milligram/1 each conventional release oral tablet (clinical drug)
capmatinib
proto-oncogene proteins c-met
MET Exon 14 Skipping Mutation
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
bronchial neoplasms
Advanced Lung Non-Small Cell Carcinoma
Refractory Lung Non-Small Cell Carcinoma
Tyrosine Kinase Inhibitors

---
https://ansm.sante.fr/tableau-atu-rtu/capmatinib-150-mg-et-200-mg-comprimes-pellicules
2021
false
false
false
France
French
Tyrosine Kinase Inhibitors
package leaflet
summary of product characteristics
guidelines for drug use
capmatinib
capmatinib
Product containing precisely capmatinib 150 milligram/1 each conventional release oral tablet (clinical drug)
Product containing precisely capmatinib 200 milligram/1 each conventional release oral tablet (clinical drug)
administration, oral
adult
carcinoma, non-small-cell lung
capmatinib
proto-oncogene proteins c-met
c-Met Inhibitor
bronchial neoplasms
Locally Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
mutation
MET Exon 14 Mutation
imidazoles
triazines
imidazoles
triazines

---
Nous contacter.
06/06/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.